107 related articles for article (PubMed ID: 30630159)
1. Autoimmune Cytopenias Occurring after Treatment with Chemoimmunotherapy for Non-Hodgkin Lymphomas.
Oka S; Nohgawa M
Acta Haematol; 2019; 141(2):79-83. PubMed ID: 30630159
[TBL] [Abstract][Full Text] [Related]
2. Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: A retrospective cohort study.
De Angelis F; Tosti ME; Capria S; Russo E; D'Elia GM; Annechini G; Stefanizzi C; Foà R; Pulsoni A
Leuk Res; 2015 Dec; 39(12):1382-8. PubMed ID: 26547259
[TBL] [Abstract][Full Text] [Related]
3. Infectious diseases and immunological markers associated with patients with non-Hodgkin lymphoma treated with rituximab.
de Souza KJ; Ferro RS; Prestes-Carneiro LE; Carrilho PAM; Vasconcelos DM
Immunopharmacol Immunotoxicol; 2018 Feb; 40(1):13-17. PubMed ID: 29094629
[TBL] [Abstract][Full Text] [Related]
4. Incidence of interstitial pneumonitis in non-Hodgkin's lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab.
Zhou T; Shen Q; Peng H; Chao T; Zhang L; Huang L; Yang K; Thapa S; Yu S; Jiang Y
Ann Hematol; 2018 Jan; 97(1):141-147. PubMed ID: 29086009
[TBL] [Abstract][Full Text] [Related]
5. Kinetics of hematogones in bone marrow samples from patients with non-Hodgkin lymphomas treated with rituximab-containing regimens: a flow cytometric study.
Carulli G; Ottaviano V; Sammuri P; Domenichini C; Guerri V; Rousseau M; Ciancia EM; Ciabatti E; Petrini M
Int J Hematol; 2015 Jul; 102(1):59-66. PubMed ID: 25953308
[TBL] [Abstract][Full Text] [Related]
6. Enteroviral infection in patients treated with rituximab for non-Hodgkin lymphoma: a case series and review of the literature.
Grisariu S; Vaxman I; Gatt M; Elias S; Avni B; Arad A; Pasvolsky O; Raanani P; Paltiel O
Hematol Oncol; 2017 Dec; 35(4):591-598. PubMed ID: 27734521
[TBL] [Abstract][Full Text] [Related]
7. Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab.
Salmasi G; Li M; Sivabalasundaram V; Panzarella T; Tsang R; Kukreti V; Crump M; Kuruvilla J
Leuk Lymphoma; 2015 Jun; 56(6):1659-64. PubMed ID: 25356925
[TBL] [Abstract][Full Text] [Related]
8. Post-chemotherapy cognitive impairment in patients with B-cell non-Hodgkin lymphoma: a first comprehensive approach to determine cognitive impairments after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or rituximab and bendamustine.
Zimmer P; Mierau A; Bloch W; Strüder HK; Hülsdünker T; Schenk A; Fiebig L; Baumann FT; Hahn M; Reinart N; Hallek M; Elter T
Leuk Lymphoma; 2015 Feb; 56(2):347-52. PubMed ID: 24738942
[TBL] [Abstract][Full Text] [Related]
9. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
[TBL] [Abstract][Full Text] [Related]
10. Tolerability and efficacy of rituximab-containing immunochemotherapy in patients with B-cell non-Hodgkin lymphoma receiving hemodialysis.
Ochi Y; Hiramoto N; Ono Y; Yoshioka S; Tabata S; Yonetani N; Matsushita A; Imai Y; Ishikawa T
Leuk Lymphoma; 2016 Aug; 57(8):1945-8. PubMed ID: 26689650
[No Abstract] [Full Text] [Related]
11. Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients.
D'Arena G; Simeon V; Laurenti L; Cimminiello M; Innocenti I; Gilio M; Padula A; Vigliotti ML; De Lorenzo S; Loseto G; Passarelli A; Di Minno MND; Tucci M; De Feo V; D'Auria F; Silvestris F; Di Minno G; Musto P
Leuk Lymphoma; 2017 Nov; 58(11):2633-2641. PubMed ID: 28367662
[TBL] [Abstract][Full Text] [Related]
12. Evans syndrome after autologous bone marrow transplant for recurrent Hodgkin's disease.
Keung YK; Cobos E; Bolanos-Meade J; Issarachai S; Brideau A; Morgan D
Bone Marrow Transplant; 1997 Dec; 20(12):1099-101. PubMed ID: 9466285
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma.
Luminari S; Goldaniga M; Cesaretti M; Orsucci L; Tucci A; Pulsoni A; Salvi F; Arcaini L; Carella AM; Tedeschi A; Pinto A; Stelitano C; Baldini L
Leuk Lymphoma; 2016; 57(4):880-7. PubMed ID: 26379040
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas.
Fabbri A; Cencini E; Rigacci L; Bartalucci G; Puccini B; Dottori R; Gozzetti A; Bosi A; Bocchia M
Leuk Lymphoma; 2014 Apr; 55(4):781-5. PubMed ID: 23876098
[TBL] [Abstract][Full Text] [Related]
15. Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma.
Fowler NH; Nastoupil LJ; Hagemeister FB; Neelapu SS; Fayad LE; LeBlanc D; Samaniego F; Cheah CY
Haematologica; 2015 Nov; 100(11):e454-7. PubMed ID: 26250576
[No Abstract] [Full Text] [Related]
16. Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy.
Qian L; Zhou C; Shen J; Cen J; Yin W
Oncotarget; 2016 May; 7(18):25783-90. PubMed ID: 27029056
[TBL] [Abstract][Full Text] [Related]
17. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
[TBL] [Abstract][Full Text] [Related]
18. A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy.
Rosenthal A; Dueck AC; Ansell S; Gano K; Conley C; Nowakowski GS; Camoriano J; Leis JF; Mikhael JR; Keith Stewart A; Inwards D; Dingli D; Kumar S; Noel P; Gertz M; Porrata L; Russell S; Colgan J; Fonseca R; Habermann TM; Kapoor P; Buadi F; Leung N; Tiedemann R; Witzig TE; Reeder C
Am J Hematol; 2017 May; 92(5):467-472. PubMed ID: 28230270
[TBL] [Abstract][Full Text] [Related]
19. Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients.
Zinzani PL; Pellegrini C; Broccoli A; Gandolfi L; Stefoni V; Casadei B; Maglie R; Argnani L; Pileri S
Hematol Oncol; 2015 Sep; 33(3):141-6. PubMed ID: 24986783
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.
Srour SA; Li S; Popat UR; Qazilbash MH; Lozano-Cerrada S; Maadani F; Alousi A; Kebriaei P; Anderlini P; Nieto Y; Jones R; Shpall E; Champlin RE; Hosing C
Br J Haematol; 2017 Aug; 178(4):561-570. PubMed ID: 28485023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]